Close Menu


The company has exclusively licensed inventions related to the modulation of miR-146 and miR-155, key mediators of the inflammatory response.

Chris Earl, Corey Goodman, Evan Melrose

Miragen Therapeutics, which holds the rights to the discovery, is interested in seeing the work advance. But a company official said that development of a miRNA-targeting drug for ALS would likely only occur in earnest with a partner.

Papers of Note: Dec 10, 2009


RNAi-Related Papers Published November 2009

IP Update: Dec 10, 2009


USPTO Publishes One Patent, Ten Patent Applications Related to RNAi

A Santaris official also confirmed that an option giving GlaxoSmithKline an option to license the drug has expired, and that deals with other companies are underway.

Originally developed in the lab of Phillip Sharp at the Massachusetts Institute of Technology, miRNA sponges are transcripts expressed from strong promoters that contain multiple tandem binding sites to an miRNA of interest.

IP Update: Dec 3, 2009


USPTO Publishes Seven Patents, Fifteen Patent Applications Related to RNAi

The patent, No. 7,592,441, relates to the human microRNA miR-193b, as well as complementary probes and vectors, the company said.

Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.


The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.